U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Recent Additions

CDC Stacks Public Health Publications

This page includes the documents that were newly added to the repository within the last 30 days.

Showing 861 - 880 of 1003 results
  • MMRV 2021
    واکسن MMRV (سرخک، اوریون، سرخجه و آبله‌مرغان): آنچه باید بدانید [2021]
    Centers for Disease Control and Prevention (U.S.)
    08/06/2021 | Vaccine Information Statement
    A VIS یا Vaccine Information Statement یک سند است که توسط CDC تهیه شده و دریافت‌کنندگان واکسن - یا والدین یا نمایندگان قانونی آن‌ها - را در مورد فواید و خطرات واکسنی که دریافت می‌کنند، آگاه می‌سازد. تمام ارائه‌دهندگان واکسن، دولتی یا خصوصی، طبق قانون آسیب‌های دوران کودکی ناشی از واکسن https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCO ...
    07/29/2026
    Supporting Files
  • MMRV 2021
    واکسن MMRV (سرخک، اوریون، سرخجه و چیچک): آنچه باید بدانید [2021]
    Centers for Disease Control and Prevention (U.S.)
    08/06/2021 | Vaccine Information Statement
    A VIS یا Vaccine Information Statement یک سند است که توسط CDC تهیه می‌شود و دریافت‌کنندگان واکسن - یا والدین یا نمایندگان قانونی آنان - را در مورد فواید و خطرات واکسنی که دریافت می‌کنند، آگاه می‌سازد. همه ارائه‌دهندگان واکسن، چه دولتی و چه خصوصی، مطابق با قانون صدمات دوران کودکی ناشی از واکسن https://www.govinfo.gov/content/pkg/USCODE-2010-title42/ ...
    07/29/2026
    Supporting Files
  • MMRV 2021
    MMRV တက်ကဆေး (ဟားမ၊ မမ့်၊ ရူဘဲလာနှင့် ဂျာဇေးလား): သင် သိထားရမည့် အချက်အလက်များ [2021]
    Centers for Disease Control and Prevention (U.S.)
    08/06/2021 | Vaccine Information Statement
    A VIS သို့မဟုတ် Vaccine Information Statement သည် CDC မှ ထုတ်လုပ်ထားသော စာတမ်းတစ်စောင်ဖြစ်ပြီး တက်ကဆေးထိုးခံယူသူများ - သို့မဟုတ် သူတို့၏ မိဘများ သို့မဟုတ် တရားဝင့် ကိုယ်စားပြုသူများ - သည် ကိုယ်တို့ထိုးခံယူမည့် တက်ကဆေး၏ အကျိုးကျေးဇူးများနှင့် အန္တရာယ်များအကြောင်းကို အသိပေးထားခြင်း ဖြစ်သည်။ အများပြည်သူ သို့မဟုတ် အထူးဒါသဖြစ်စေ တက်ကဆေးပေးနေသူများအားလုံ ...
    07/29/2026
    Supporting Files
  • MMRV 2021
    MMRV টিকা (হাম, মাম্পস, রুবেলা এবং জলবসন্ত): আপনার জানা প্রয়োজন [2021]
    Centers for Disease Control and Prevention (U.S.)
    08/06/2021 | Vaccine Information Statement
    A VIS বা Vaccine Information Statement হল CDC কর্তৃক প্রস্তুত একটি নথি, যা টিকা গ্রহণকারীদের - অথবা তাদের বাবা-মা বা আইনগত প্রতিনিধিদের - তারা যে টিকা গ্রহণ করছেন তার উপকারিতা এবং ঝুঁকি সম্পর্কে জানায়। সকল টিকা প্রদানকারী, সরকারি বা বেসরকারি, National Vaccine Childhood Injury Act https://www.govinfo.gov/content/pkg/USCODE-2010-title42/pdf/USCODE-2 ...
    07/29/2026
    Supporting Files
  • MMRV 2021
    MMRV պատվաստանյութ (կարմրախտ, խոզակ, կարմրուկ և ջրծաղիկ). Ինչ է անհրաժեշտ לדעת [2021]
    Centers for Disease Control and Prevention (U.S.)
    08/06/2021 | Vaccine Information Statement
    A VIS կամ Պատվաստանյութի տեղեկատվական հայտարարություն CDC-ի կողմից մշակված փաստաթուղթ է, որը տեղեկացնում է պատվաստանյութ ստացողներին - կամ նրանց ծնողներին կամ օրինական ներկայացուցչին - այն պատվաստանյութի օգուտների և ռիսկերի մասին, որը նրանք ստանում են։ Բոլոր պատվաստանյութ տրամադրողները, պետական թե մասնավոր, պարտավոր են՝ ըստ Պատվաստանյութերից երեխան ...
    07/29/2026
    Supporting Files
  • Morbidity and Mortality Weekly Report MMWR Surveillance Summaries Vol 75 No 5 July 30 2026
    Morbidity and Mortality Weekly Report (MMWR): Surveillance Summaries / Vol. 75 / No. 5, July 30, 2026
    July 30, 2026 | Surveillance Summaries: Morbidity and Mortality Weekly Report (MMWR)
    Invasive mold diseases (IMDs) are rare, life-threatening infections that primarily affect persons with immunocompromising conditions. The most common molds associated with IMDs are Aspergillus spp., Mucorales (e.g., Mucor spp., Rhizomucor spp., and Rhizopus spp.), Fusarium spp., and Scedosporium spp. IMDs can affect the lungs, sinuses, skin, centra ...
    07/29/2026
  • Vaccine Storage and Handling Toolkit Addendum for SNSsuppled Jynneos 202607
    Vaccine Storage and Handling Toolkit Addendum: for SNS-suppled Jynneos [2026/07]
    Centers for Disease Control and Prevention (CDC) (U.S.). National Center for Immunization and Respiratory Diseases. Immunization Services Division
    2026/07/01 | National Center for Immunization and Respiratory Diseases (NCIRD)
    Proper vaccine storage and handling practices are essential for protecting patients by ensuring product efficacy and quality, preventing unnecessary revaccination, minimizing vaccine wastage, and ensuring a viable vaccine supply. Ultimately, adhering to vaccine storage and handling guidelines helps improve patients' health by preventing disease.The ...
    07/28/2026
    Current Supporting Files
  • Vaccine Storage and Handling Toolkit Key Resources 202607
    Vaccine Storage and Handling Toolkit: Key Resources [2026/07]
    Centers for Disease Control and Prevention (CDC) (U.S.). National Center for Immunization and Respiratory Diseases. Immunization Services Division
    2026/07/01 | National Center for Immunization and Respiratory Diseases (NCIRD)
    Proper vaccine storage and handling practices are essential for protecting patients by ensuring product efficacy and quality, preventing unnecessary revaccination, minimizing vaccine wastage, and ensuring a viable vaccine supply. Ultimately, adhering to vaccine storage and handling guidelines helps improve patients' health by preventing disease.The ...
    07/28/2026
    Current Supporting Files
  • Vaccine Storage and Handling Toolkit 202607
    Vaccine Storage and Handling Toolkit [2026/07]
    Centers for Disease Control and Prevention (CDC) (U.S.). National Center for Immunization and Respiratory Diseases. Immunization Services Division
    2026/07/01 | National Center for Immunization and Respiratory Diseases (NCIRD)
    Proper vaccine storage and handling practices are essential for protecting patients by ensuring product efficacy and quality, preventing unnecessary revaccination, minimizing vaccine wastage, and ensuring a viable vaccine supply. Ultimately, adhering to vaccine storage and handling guidelines helps improve patients' health by preventing disease.The ...
    07/28/2026
    Current Supporting Files
  • UPDATE Vaccine Adverse Event Reporting System VAERS Data on Febrile Seizures after Vaccination with Fluzone a 20102011 Trivalent Inactivated Vaccine in Children Data through December 13 2010
    UPDATE: Vaccine Adverse Event Reporting System (VAERS) Data on Febrile Seizures after Vaccination with Fluzone®, a 2010-2011 Trivalent Inactivated Vaccine, in Children: Data through December 13, 2010
    Centers for Disease Control (U.S.). Food and Drug Administration
    2010 | H1N1 Flu Update
    Special VAERS update detailing an increased signal of febrile seizure reports in children aged 6-23 months following Fluzone TIV vaccination, including case characteristics, timing, severity, and no changes to vaccine recommendations.
    07/28/2026
  • 20162017 Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System VAERS
    2016-2017 Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System (VAERS)
    Centers for Disease Control (U.S.). Food and Drug Administration
    2016 | H1N1 Flu Update
    Season overview listing 2016-17 vaccine types, ACIP vote against LAIV use for the season, newly licensed Fluad and expanded Flublok approval, febrile seizure information, and VAERS WONDER search instructions.
    07/28/2026
  • 20152016 Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System VAERS
    2015-2016 Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System (VAERS)
    Centers for Disease Control (U.S.). Food and Drug Administration
    2015 | H1N1 Flu Update
    Season overview listing 2015-16 vaccine types, ACIP removal of LAIV preferential recommendation for children, LAIV warnings/precautions, egg-allergy guidance, febrile seizure information, and VAERS WONDER search instructions.
    07/28/2026
  • 20142015 Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System VAERS
    2014-2015 Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System (VAERS)
    Centers for Disease Control (U.S.). Food and Drug Administration
    2014 | H1N1 Flu Update
    Season overview noting unchanged 2014-15 vaccine formulation from prior year, describing available vaccine types (IIV3, IIV4, LAIV, cell-based, recombinant), egg-allergy guidance, febrile seizure monitoring history, and VAERS WONDER search instructions.
    07/28/2026
  • 20132014 Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System VAERS
    2013-2014 Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System (VAERS)
    Centers for Disease Control (U.S.). Food and Drug Administration
    2013 | H1N1 Flu Update
    Season overview describing the expanded range of 2013-14 influenza vaccines (IIV3, IIV4, LAIV, cell-based, recombinant), egg-allergy guidance, febrile seizure monitoring history and findings through 2012-13, and VAERS WONDER search instructions.
    07/28/2026
  • 20122013 Trivalent Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System VAERS
    2012-2013 Trivalent Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System (VAERS)
    Centers for Disease Control (U.S.). Food and Drug Administration
    2012 | H1N1 Flu Update
    Season overview describing 2012-13 vaccine formulation changes, available vaccine types (TIV, Fluzone High Dose, LAIV, intradermal), follow-up on 2010-11 febrile seizure study findings, egg-allergy vaccination guidance, and VAERS WONDER search instructions.
    07/28/2026
  • Summary of 20102011 Trivalent Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System Data through Jan 25 2011
    Summary of 2010-2011 Trivalent Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System :Data through Jan. 25, 2011
    Centers for Disease Control (U.S.). Food and Drug Administration
    March 7, 2011 | H1N1 Flu Update
    Monthly VAERS summary of adverse event reports following 2010-2011 trivalent influenza vaccination, including counts of serious events, deaths, GBS, and febrile seizure signal in children, as of January 25, 2011.
    07/28/2026
  • Summary of 20102011 Trivalent Influenza Vaccine Data from the US Vaccine Adverse Event Reporting SystemData through December 14 2010
    Summary of 2010-2011 Trivalent Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System:Data through December 14, 2010
    Centers for Disease Control (U.S.). Food and Drug Administration
    January 21, 2011 | H1N1 Flu Update
    Monthly VAERS summary of adverse event reports following 2010-2011 trivalent influenza vaccination, including counts of serious events, deaths, GBS, and febrile seizure signal in children, as of December 14, 2010.
    07/28/2026
  • Summary of 20102011 Trivalent Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System Data through December 28 2010
    Summary of 2010-2011 Trivalent Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System: Data through December 28, 2010
    Centers for Disease Control (U.S.). Food and Drug Administration
    February 4, 2010 | H1N1 Flu Update
    Monthly VAERS summary of adverse event reports following 2010-2011 trivalent influenza vaccination, including counts of serious events, deaths, GBS, and febrile seizure signal in children, as of December 28, 2010.
    07/28/2026
  • Summary of 20102011 Trivalent Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System Data through Feb 25 2011
    Summary of 2010-2011 Trivalent Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System: Data through Feb. 25, 2011
    Centers for Disease Control (U.S.). Food and Drug Administration
    April 5, 2010 | H1N1 Flu Update
    Monthly VAERS summary of adverse event reports following 2010-2011 trivalent influenza vaccination, including counts of serious events, deaths, GBS, and febrile seizure signal in children, as of February 25, 2011.
    07/28/2026
  • 20112012 Trivalent Influenza Vaccine Data from the US Vaccine Adverse Event Reporting System VAERS
    2011-2012 Trivalent Influenza Vaccine Data from the U.S. Vaccine Adverse Event Reporting System (VAERS)
    Centers for Disease Control (U.S.). Food and Drug Administration
    2011 | H1N1 Flu Update
    Season overview noting the 2011-12 vaccine formulation is unchanged from 2010-11, describes available vaccine types (TIV, LAIV, new intradermal product), references prior season's febrile seizure signal, and provides VAERS WONDER search instructions.
    07/28/2026
861 - 880 / 1003
 Found an issue?
Send us an email at: